HOLLISTON, Mass., March 28, 2017 /PRNewswire/ -- Biostage, Inc.
(Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology
company developing bioengineered organ implants to treat cancers
and other life-threatening conditions of the esophagus, bronchus
and trachea, today announced that Jim McGorry, CEO of Biostage,
will present on the 3D Printing and BioEngineering panel at
the MassBio 2017 Annual Meeting on Thursday,
March 30, 2017 at 2:30 PM ET
in Cambrige, Massachussetts. The 3D Printing and
BioEngineering panel will address the developments and
discoveries in 3D printing in medicine and research, focusing on
how advances in 3D printing are pushing the boundaries of medical
innovation.
As part of his participation, Mr. McGorry will discuss the
Company's proprietary Cellframe™ technology platform,
which is engineered to stimulate the body's signaling pathways and
natural healing process to regenerate and restore organ function.
Combining a synthetic scaffold with tissue engineering and cell
biology, Biostage's Cellframe platform will be used to create organ
specific Cellspan implants for the esophagus, bronchus and trachea.
Mr. McGorry will also discuss the Company's lead product candidate,
the Cellspan esophageal implant, which is being developed to treat
adult esophageal cancer. Biostage expects to commence its
first-in-human studies for its Cellspan esophageal implant before
the end of 2017.
In addition to developing its Cellspan esophageal implant for
use in adults with esophageal cancer, the Company is evaluating its
Cellspan esophageal implant for use to treat pediatric esophageal
atresia (EA). EA is a rare birth defect in which a baby is born
with a gap between the upper and lower esophagus, which
effects about 1 in 2,500 babies in the U.S. Biostage remains
encouraged with its EA co-development efforts with Connecticut
Children's Medical Center. The Company is also evaluating
additional partnerships with children's hospitals showing strong
interest in this
program.
About MassBio
MassBio is a not-for-profit organization founded in 1985 that
represents and provides services and support for the world's
leading life sciences supercluster.
MassBio is committed to advancing Massachusetts' leadership in the life sciences
to grow the industry, add value to the healthcare system and
improve patient lives.
Representing 975+ biotechnology companies, academic
institutions, disease foundations and other organizations involved
in life sciences and healthcare, MassBio leverages its unparalleled
network of innovative companies and industry thought leaders to
advance policy and promote education, while providing member
programs, events, industry information, and services.
About Cellframe™ Technology
The Company's proprietary Cellframe technology is designed to
harness the full potential of the in vivo microenvironment
to achieve tissue regeneration and restore organ function. It
employs a multi-step process in which the patient's own stem cells
would be taken from a simple adipose/fat tissue biopsy, expanded
and banked, and then seeded onto a proprietary scaffold that mimics
the natural dimensions of the organ being regenerated. After
several days in a rotating bioreactor, the biocompatible scaffold
containing the stem cells will then be ready to be implanted.
Preclinical studies suggest that the organ implant signals the stem
cell niche in the surrounding native tissue to guide the
regeneration of a biological structure. This technology is based on
the concept of in situ tissue regeneration using the body's
own biologic resources and reparative capability in combination
with tissue-specific biomaterials implanted at the sites of disease
or injury.
About Biostage
Biostage is a biotechnology company developing bioengineered
organ implants based on the Company's new Cellframe™
technology which combines a proprietary biocompatible scaffold with
a patient's own stem cells to create Cellspan™ organ
implants. Cellspan implants are being developed to treat
life-threatening conditions of the esophagus, bronchus or trachea
with the hope of dramatically improving the treatment paradigm for
patients. Based on its preclinical data, Biostage has selected
life-threatening conditions of the esophagus as the initial
clinical application of its technology.
Cellspan implants are currently being advanced and tested in
collaborative preclinical studies. Preclinical, large-animal safety
studies, conducted in compliance with the FDA Good Laboratory
Practice (GLP) regulations, for the Company's Cellspan Esophageal
Implant product candidate are ongoing, in support of Biostage's
goal of filing an Investigational New Drug application (IND) with
the U.S. FDA in the third quarter of 2017. The IND will seek
approval to initiate clinical trials for its esophageal implant
product candidate in humans.
For more information, please visit www.biostage.com and connect
with the Company on Twitter and LinkedIn.
Forward-Looking Statements:
Some of the statements in this press release are
"forward-looking" and are made pursuant to the safe harbor
provision of the Private Securities Litigation Reform Act of 1995.
These "forward-looking" statements in this press release include,
but are not limited to, statements relating to the development
expectations and regulatory approval of any of our product
candidates, including those utilizing our Cellframe technology, by
the U.S. Food and Drug Administration, the European Medicines
Agency or otherwise, which expectations or approvals may not be
achieved or obtained on a timely basis or at all; or success with
respect to any collaborations, clinical trials and other
development and commercialization efforts of our product
candidates, including those utilizing our Cellframe
technology, which such success may not be achieved or
obtained on a timely basis or at all. These statements involve
risks and uncertainties that may cause results to differ materially
from the statements set forth in this press release, including,
among other things, our ability to obtain and maintain regulatory
approval for our products; plus other factors described under the
heading "Item 1A. Risk Factors" in our Annual Report on Form 10-K
for the fiscal year ended December 31,
2016 or described in our other public filings. Our results
may also be affected by factors of which we are not currently
aware. The forward-looking statements in this press release speak
only as of the date of this press release. Biostage expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to such statements to reflect any change in
its expectations with regard thereto or any changes in the events,
conditions or circumstances on which any such statement is
based.
Investor Relations
Contacts:
|
|
Tom
McNaughton
|
Jenene
Thomas
|
Chief Financial
Officer
|
Jenene Thomas
Communications LLC
|
774-233-7321
|
(908)
938-1475
|
tmcnaughton@biostage.com
|
jtc@jenenethomascommunications.com
|
|
|
|
|
Media
Contacts:
|
|
David Schull or
Maggie Beller
|
|
Russo Partners
LLC
|
|
212-845-4271 or
646-942-5631
|
|
Email:
Maggie.beller@russopartnersllc.com
|
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biostage-to-participate-at-the-massbio-2017-annual-meeting-300430059.html
SOURCE Biostage, Inc.